Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
NCT05008276 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2025-03-24
Summary
Early diabetic kidney disease (DKD) occurs in 50-70% of youth with type 2 diabetes (T2D) and confers high lifetime risk of dialysis and premature death. Youth-onset T2D typically manifests during or shortly after puberty in adolescents with obesity. Epidemiological data implicate puberty as an accelerator of kidney disease in youth with obesity and diabetes and the investigators posit that the link between puberty and T2D-onset may explain the high burden of DKD in youth-onset T2D. A better understanding of the impact of puberty on kidney health is needed to promote preservation of native kidney function, especially in youth with T2D.
Conditions
- Type 2 Diabetes Mellitus
- Diabetic Kidney Disease
- Adolescent Obesity
- Pre Diabetes
- Kidney Hypoxia
- Puberty
Interventions
- DRUG
-
Aminohippurate Sodium Inj 20%
Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
- DRUG
-
Iohexol Inj 300 MG/ML
Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
- DRUG
-
Dextran 40
Diagnostic aid/agent used to measure glomerular size and selectivity
Sponsors & Collaborators
-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
collaborator NIH -
Seattle Children's Hospital
collaborator OTHER -
University of Colorado, Denver
collaborator OTHER -
Petter Bjornstad
lead OTHER
Principal Investigators
-
Petter Bjornstad, MD · University of Washington - Medicine Diabetes Institute
Eligibility
- Min Age
- 8 Years
- Max Age
- 14 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-09-27
- Primary Completion
- 2027-12-01
- Completion
- 2027-12-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes
NCT01500798 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
NCT07271186 ·Status: RECRUITING ·Phase: PHASE2
-
Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial
NCT01581476 ·Status: COMPLETED ·Phase: PHASE3
-
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
NCT01601236 ·Status: COMPLETED ·Phase: PHASE2
-
PeRsOnalising Treatment Of Diabetic Nephropathy:
NCT03509454 ·Status: COMPLETED
-
Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy
NCT03622762 ·Status: UNKNOWN ·Phase: PHASE2
-
Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)
NCT02818192 ·Status: RECRUITING
-
A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy
NCT01200394 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Pyridorin in Patients With Diabetic Nephropathy
NCT00320021 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
NCT01549769 ·Status: TERMINATED ·Phase: PHASE1
-
Effect of Elevated Plasma-Free-Fatty-Acids on Renal Hemodynamic Parameters
NCT00431665 ·Status: COMPLETED ·Phase: NA
-
Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
NCT01053936 ·Status: COMPLETED ·Phase: PHASE2
-
PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)
NCT00729365 ·Status: TERMINATED ·Phase: PHASE3
-
Pentoxifylline Effect in Patients With Diabetic Nephropathy.(PENFOSIDINE STUDY)
NCT03664414 ·Status: UNKNOWN ·Phase: PHASE4
-
Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
NCT02251067 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945 ·Status: RECRUITING ·Phase: PHASE3
-
Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia
NCT06147232 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function
NCT01759576 ·Status: COMPLETED ·Phase: PHASE1
-
Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
NCT05018416 ·Status: COMPLETED ·Phase: PHASE2
-
Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes
NCT01551446 ·Status: WITHDRAWN ·Phase: PHASE1
-
Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function
NCT01478399 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
NCT00976495 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment
NCT01555008 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Effects Icodextrin Versus Dianeal on Insulin Resistance in Nondiabetic Automated Peritoneal Dialysis Patients
NCT01021878 ·Status: COMPLETED ·Phase: PHASE4
-
Mycophenolate Mofetil, Carnitine and PDE5 Inhibitor, Three Potential Treatments for Resistant Proteinuria Slowing Diabetic Nephropathy Deterioration
NCT01566006 ·Status: UNKNOWN ·Phase: NA